Advertisement

Topics

GSK seeks COPD approval for mepolizumab

16:15 EST 8 Nov 2017 | pharmaphorum

GlaxoSmithKline has asked the US regulator to expand the licence of its injected lung drug mepolizumab, to include chronic obstructive pulmonary disease (COPD). Under the brand name Nucala, mepolizumab was first approved in November 2015 as an add...

Original Article: GSK seeks COPD approval for mepolizumab

NEXT ARTICLE

More From BioPortfolio on "GSK seeks COPD approval for mepolizumab"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...